title: Osteoprotegerin ameliorates sciatic nerve crush induced bone loss.
abstract: This study examines the ability of osteoprotegerin (OPG) to prevent the local bone resorption caused by sciatic nerve damage. Sixty-five 18-week-old male mice were assigned to one of six groups (n = 10-11/group). A baseline control group was sacrificed on day zero of the 10-day study. The remaining groups were placebo sham operated, placebo nerve crush (Plac NC) operated, 0.1 mg/kg/day OPG + nerve crush (LOW), 0.3 mg/kg/day OPG + nerve crush (MED), and 1.0 mg/kg/day OPG + nerve crush (HI). Nerve crush or sham operations were performed on the right leg. The left leg served as a contralateral control to the nerve crushed (ipsilateral) leg. The difference in mass between the right and left femur and tibia was examined. Additionally, quantitative histomorphometry was performed on the right and left femur and tibia diaphyses. Nerve crush resulted in a significant loss of bone mass in the ipsilateral side compared to the contralateral side. Bone mass for the ipsilateral bones of the Plac NC group were significantly reduced by 3.8% in the femur and 3.5% in the tibia compared to the contralateral limb. The percent diminution was reduced for OPG treated mice compared to the Plac NC group for both the femur and tibia. In the femur, the percent reduction of ipsilateral bone mass was reduced to 1.0% (LOW), 1.3% (MED) and 1.6% (HI) compared to the contralateral limb. In the tibia, loss of bone mass in the ipsilateral limb was reduced to 1.4% (LOW), 1.4% (MED), and 2.4% (HI) compared to the contralateral. OPG also decreased the amount of tibial endocortical resorption compared to the Plac NC group. In summary, OPG mitigated bone loss caused by damage to the sciatic nerve.
authors.affiliation: Department of Aerospace Engineering Sciences, BioServe Space Technologies, University of Colorado, Boulder 80309-0429, USA. ted.bateman@colorado.edu
authors.forename: T A
authors.initials: TA
authors.lastname: Bateman
authors.forename: C R
authors.initials: CR
authors.lastname: Dunstan
authors.forename: D L
authors.initials: DL
authors.lastname: Lacey
authors.forename: V L
authors.initials: VL
authors.lastname: Ferguson
authors.forename: R A
authors.initials: RA
authors.lastname: Ayers
authors.forename: S J
authors.initials: SJ
authors.lastname: Simske
mesh_terms: D000818:Animals; D001862:Bone Resorption / Q000188:drug therapy* / Q000473:pathology; D018483:Diaphyses / Q000473:pathology; D004195:Disease Models, Animal; D005269:Femur / Q000294:innervation / Q000473:pathology; D006023:Glycoproteins / Q000494:pharmacology*; D006811:Humerus / Q000033:anatomy & histology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009409:Nerve Crush; D009929:Organ Size; D053244:Osteoprotegerin; D018160:Receptors, Cytoplasmic and Nuclear; D018124:Receptors, Tumor Necrosis Factor; D012584:Sciatic Nerve / Q000502:physiology*; D013977:Tibia / Q000294:innervation / Q000473:pathology
chemical_list: D006023:Glycoproteins; D053244:Osteoprotegerin; D018160:Receptors, Cytoplasmic and Nuclear; D018124:Receptors, Tumor Necrosis Factor; C506031:Tnfrsf11b protein, mouse